期刊文献+

左旋多巴分析方法研究概况 被引量:4

Review of the analytical methods for levodopa
暂未订购
导出
摘要 左旋多巴用于治疗帕金森病已有30多年的历史,目前在临床上仍占有重要地位。近年来左旋多巴的体内外分析方法都取得了很大进展,紫外分光光度法、高效液相色谱法在左旋多巴的体内外分析中应用最广,流动注射自动分析方法和毛细管电泳法等也有广泛应用,可见-紫外分光光度检测器、荧光检测器、电化学检测器、化学发光检测、蒸发光散射检测器等新型检测器都有报道。本文通过查阅文献,对制剂中左旋多巴原药物和生物样品中左旋多巴及其代谢物的分离分析方法进行了概括和总结。 Levodopa has been used in the treatment of Parkinson's disease for more than 30 years, and up to now it still plays a very important role in clinic. Much progress has been made in the analytical methods in vivo and in vitro for levodopa: UV spectrophotometry and HPLC are most widely used. Flow injection analysis and capillary electrophoresis are also adopted widely in recent years. New detectors such as UV detector, fluorescent detector, electrochemical detector, chemiluminescent detector and evaporative light-scattering detector are reported. In this article, the analytic methods for levodopa are reviewed.
作者 迟强 梅兴国
出处 《国际药学研究杂志》 CAS 2007年第5期369-373,共5页 Journal of International Pharmaceutical Research
关键词 左旋多巴 分析方法 levodopa analytical method
  • 相关文献

参考文献26

  • 1袁进,龙启才,赵树进.左旋多巴治疗帕金森病致症状波动的机制[J].中国医院药学杂志,2001,21(7):421-423. 被引量:7
  • 2[3]Nagaraja P,Vasantha RA,Sunitha KR.A sensitive and selective spectrophotometric estimation of catechol derivatives in pharmaceutical preparations[J].Talanta,2001,55(6):1039-1046.
  • 3[4]Damiani PC,Moschetti AC,Rovetto AJ,et al.Design and optimization of a chemo-metrics-assisted spectrophotometric method for the simultaneous determination of levodopa and carbidopa in pharmaceutical products[J].Anal Chim Acta,2005,543(1/2):192-198.
  • 4[5]Tait RJ,Finnin BC,Reed BL.A study of irreversible electrode processes under steady-state flowing solution conditions with a microelectrode based scanning electrochemical detector[J].Anal Chim Acta,1996,324(1):1-11.
  • 5[6]WoodAT,HallMR.Reversed-phase high-performance liquid chromatography of catecholamines and indoleamines using a simple gradient solvent system and native fluorescence detection[J].J Chromatogr B Biomed Sci Appl,2000,744(1):221-225.
  • 6[7]Neves HJC,Morais ZB.HPLC assay of underivalized free amino acids with column switching and evaporative light-scattering detection[J].J High Resolut Chromatogr,1997,20(2):115-118.
  • 7[8]Fanali S,Pucci V,Sabbioni C,et al.Quality control of benserazide-levodopa and carbidopa-levodopa tablets by capillary zone electrophoresis[J].Electrophoresis,2000,21(12):2431-2437.
  • 8[9]Lee JH,Choi OK,Jung HS,et al.Capillary electrophoresis of nonprotein and protein amino acids without derivalization[J].Electrophoresis,2000,21(5):930-934.
  • 9[10]Chen XF,Zhang JY,Zhai HL,et al.Determination of levodopa by capillary zone electrophoresis using an acidic phosphate buffer and its application in the analysis of beans[J].Food Chem,2005,92(2):381-386.
  • 10[11]Dolezalova M,Fanali S.Enantiomeric separation of dihydroxy-phenylalanine (DOPA),methyldihydroxyphenylalanine (MDOPA) and hydrazinomethyldihydroxyphenylalanine (CDOPA) by using capillary electrophoresis with sulfobutyl ether-β-cyclodextrin as a chiral selector[J].Electrophoresis,2000,21(15):3264-3269.

二级参考文献23

  • 1[1]Lees AJ. Levodopa substitution: the gold standard. Clin Neuropharmacol, 1994, 17(Suppl 3):S1
  • 2[2]Hyland K, Clayton PT. Aromatic L-amino acid decarboxylase deficiency: diagnostic methodology. Clin Chem, 1992, 38(12):2405
  • 3[3]Dethy S, Laute MA, Blercom NV, et al. Microdialysis-HPLC for plasma levodopa and metabolites monitoring in parkinsonian patients. Clin Chem, 1997, 43(5):740
  • 4[4]Fornadi F, Milani F, Werner M. Modapar dispersible in the treatment of advanced parkinson's disease. Clin Neuropharmacol, 1994, 17(Suppl 3):S7
  • 5[1]Guttman M, Burkholder J, Kish SJ, et al.[11C]RTI-32 PET studies of the dopamine transporter in early dopa naive Parkinson's disease: implication s for the symptomatic threshold[J]. Neurology,1997,48:1578.
  • 6[2]Leenders KL, Palmer AJ, Quinn N, et al. Brain dopamine met-abolism in patie nts with Parkinson's disease measured with positron emission tomography[J]. J Neurol Neurosurg Psychiatry, 1986,49:853.
  • 7[3]Fabbrini G.Motor fluctuations in Parkinson's disease-central pathophysiolog ical mechanism,part 1[J].Ann Neurol, 1988,24:366.
  • 8[4]Nagasawa H,Saito H,Kogure K, et al. 6-(18F)Fluorodopa met-abolism in patients with hemiparkinson's disease studied by positron emission tomograph y[J].J Neurol Sci,1993,115:136.
  • 9[5]Snow BJ, Tooyawa I, McGeer EG, et al. Human positronemission tomographic (18F)Fluorodopa studies correlate with dopamine cell counts and leve ls[J].Ann Neurol, 1993,34:324.
  • 10[6]Sohn YH, Metman LV, Bravi D,et al. Levodopa peak response time reflects s everity of dopamine neuron loss in Parkinson's disease. Neurology[J]. 1994,44:755.

共引文献11

同被引文献24

引证文献4

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部